Biorestorative Therapies, INC. (BRTX) — SEC Filings

Overview

Biorestorative Therapies, INC. (BRTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: BioRestorative Therapies, Inc. (BRTX) is focused on developing adult stem cell therapies for disc/spine conditions and metabolic disorders, alongside a commercial biocosmeceuticals business. In 2025, the company achieved significant milestones for its BRTX-100 program, including FDA Fast Track desig

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 3 bearish, 35 neutral, 2 mixed. The dominant filing sentiment for Biorestorative Therapies, INC. is neutral.

Filing Type Overview

Biorestorative Therapies, INC. (BRTX) has filed 22 8-K, 3 10-K, 2 S-1, 5 10-Q, 2 DEF 14A, 2 10-K/A, 1 S-1/A, 2 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• 8-K Filing — 8-K · Apr 23, 2026
• BioRestorative Therapies Accelerates BRTX-100, Eyes Phase 3 Amid Funding Gap — 10-K · Mar 26, 2026 Risk: high
  BioRestorative Therapies, Inc. (BRTX) is focused on developing adult stem cell therapies for disc/spine conditions and metabolic disorders, alongside a commerci
• BioRestorative Files S-1 for 508K Share Resale; No Proceeds to Company — S-1 · Nov 18, 2025 Risk: high
  BioRestorative Therapies, Inc. (BRTX) filed an S-1 to register 508,592 shares of common stock for resale by existing selling securityholders. The company will n
• BioRestorative Therapies Reports Q3 2025 Financials — 8-K · Nov 12, 2025 Risk: medium
  BioRestorative Therapies, Inc. filed an 8-K on November 12, 2025, reporting its third quarter 2025 financial results. The filing also includes information on Re
• BioRestorative Therapies' Net Loss Widens Amid Soaring R&D Costs — 10-Q · Nov 12, 2025 Risk: high
  BioRestorative Therapies, Inc. (BRTX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $11.0 million, up from
• BioRestorative Therapies Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 8, 2025 Risk: medium
  On October 6, 2025, BioRestorative Therapies, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
• BioRestorative Therapies Holds Annual Meeting Vote — 8-K · Sep 25, 2025 Risk: low
  BioRestorative Therapies, Inc. filed an 8-K on September 25, 2025, reporting on matters submitted to a vote of its security holders. The filing indicates that t
• BioRestorative Therapies 8-K Filing — 8-K · Aug 14, 2025 Risk: low
  BioRestorative Therapies, Inc. filed an 8-K on August 14, 2025, reporting its status as a registrant. The filing confirms its principal executive offices are lo
• BioRestorative Therapies Files Q2 2025 8-K — 8-K · Aug 12, 2025 Risk: medium
  BioRestorative Therapies, Inc. filed an 8-K on August 12, 2025, to report on its Q2 2025 earnings and provide a business update. The filing includes financial s
• BRTX Narrows Q2 Loss Amidst Zero Revenue, High Burn Rate — 10-Q · Aug 12, 2025 Risk: high
  BioRestorative Therapies, Inc. (BRTX) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company'
• BioRestorative Therapies Details Executive Equity Compensation — DEF 14A · Aug 8, 2025 Risk: medium
  BioRestorative Therapies, Inc. (BRTX) filed a DEF 14A on August 8, 2025, detailing executive compensation and equity award adjustments for the fiscal years endi
• 8-K Filing — 8-K · Jun 13, 2025
• BioRestorative Therapies Q1 2025 Update — 8-K · May 14, 2025 Risk: medium
  BioRestorative Therapies, Inc. announced its first quarter 2025 financial results and provided a business update on May 14, 2025. The company, formerly known as
• BioRestorative Therapies Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  BioRestorative Therapies, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Stem Cell Assurance, Inc., is involved in hea
• BioRestorative Therapies Changes Accountants — 8-K · Apr 21, 2025 Risk: low
  BioRestorative Therapies, Inc. announced a change in its certifying accountant on April 16, 2025. The company's previous independent registered public accountin
• BioRestorative Therapies Files 2024 10-K — 10-K · Mar 28, 2025 Risk: medium
  BioRestorative Therapies, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Stem Cell Assurance, Inc., is involve
• BioRestorative Therapies Reports 2024 Financials — 8-K · Mar 27, 2025 Risk: medium
  BioRestorative Therapies, Inc. filed an 8-K on March 27, 2025, reporting financial results for the year ended December 31, 2024, and announcing a conference cal
• BioRestorative Therapies Files 8-K — 8-K · Feb 10, 2025 Risk: low
  BioRestorative Therapies, Inc. filed an 8-K on February 10, 2025, reporting on its current activities. The filing primarily serves as a notification of informat
• 8-K Filing — 8-K · Nov 13, 2024
• BioRestorative Therapies Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its b
• BioRestorative Therapies Files 8-K on Phase 2 Data — 8-K · Nov 7, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed an 8-K on November 7, 2024, reporting preliminary Phase 2 data and a review of its third-quarter conference call. The filin
• BioRestorative Therapies Terminates Agreement, Enters New Offering Deal — 8-K · Nov 6, 2024 Risk: medium
  BioRestorative Therapies, Inc. announced on November 1, 2024, the termination of a material definitive agreement. The company also entered into a new material d
• BioRestorative Therapies Files 2023 10-K Amendment — 10-K/A · Nov 6, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed an amendment (Amendment No. 2) to its 2023 annual report on Form 10-K on November 6, 2024. The company, previously known as
• BioRestorative Therapies Holds Shareholder Vote — 8-K · Sep 23, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed an 8-K on September 23, 2024, reporting on a matter submitted to a vote of its security holders on September 19, 2024. The
• BioRestorative Therapies Reports Q2 Results — 8-K · Aug 13, 2024 Risk: low
  BioRestorative Therapies, Inc. filed an 8-K on August 13, 2024, to report its financial results for the second quarter. The filing details the company's operati
• BioRestorative Therapies Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Stem Cell Assurance, Inc., is involved in heal
• BioRestorative Therapies Sets Annual Meeting Date — DEF 14A · Aug 8, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed its definitive proxy statement on August 8, 2024, for its annual meeting scheduled for September 19, 2024. The company, pre
• BioRestorative Therapies Reports Q2 Results, Announces Conference Call — 8-K · Aug 6, 2024 Risk: medium
  BioRestorative Therapies, Inc. filed an 8-K on August 6, 2024, reporting on its second quarter results and announcing a conference call. The filing details fina
• BioRestorative Therapies Files 2023 10-K/A Amendment — 10-K/A · Jun 11, 2024 Risk: low
  BioRestorative Therapies, Inc. filed an amendment (10-K/A) on June 11, 2024, for its fiscal year ending December 31, 2023. The filing includes financial data fo
• BioRestorative Therapies Restates Financials — 8-K · May 24, 2024 Risk: medium
  BioRestorative Therapies, Inc. announced on May 23, 2024, that it will not rely on previously issued financial statements. This decision impacts financial repor
• BioRestorative Therapies Files S-1/A Amendment — S-1/A · Apr 12, 2024 Risk: low
  BioRestorative Therapies, Inc. (BRTX) filed a Amended IPO Registration (S-1/A) with the SEC on April 12, 2024. BioRestorative Therapies, Inc. filed an S-1/A reg
• BioRestorative Therapies, Inc. Files S-1 Registration Statement — S-1 · Apr 3, 2024 Risk: low
  BioRestorative Therapies, Inc. (BRTX) filed a IPO Registration (S-1) with the SEC on April 3, 2024. BioRestorative Therapies, Inc. has filed an S-1 registration
• BioRestorative Therapies, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  BioRestorative Therapies, Inc. (BRTX) filed a Annual Report (10-K) with the SEC on April 1, 2024. BioRestorative Therapies, Inc. filed its annual report for the
• BioRestorative Therapies Files 8-K with Presentation Materials — 8-K · Mar 12, 2024 Risk: low
  On March 11, 2024, BioRestorative Therapies, Inc. filed an 8-K report. The filing primarily concerns the presentation materials related to the company's busines
• Broadrick Amends BioRestorative Therapies Filing — SC 13D/A · Mar 6, 2024 Risk: medium
  Dale Broadrick filed an amendment (Amendment No. 9) to Schedule 13D on March 6, 2024, regarding BioRestorative Therapies, Inc. The filing indicates a change in
• Alstodt Amends BioRestorative Therapies Ownership Filing — SC 13D/A · Feb 15, 2024 Risk: medium
  Lance Alstodt filed an Amendment No. 2 to Schedule 13D on February 15, 2024, regarding his beneficial ownership in BioRestorative Therapies, Inc. The event requ
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• BRTX Raises $1M via Unregistered Stock & Warrant Sale — 8-K · Feb 8, 2024 Risk: medium
  BioRestorative Therapies, Inc. (BRTX) entered into a material definitive agreement on February 6, 2024, for the unregistered sale of equity securities. This inv
• BRTX Files 8-K for Reg FD Disclosure, Exhibits on Feb 5 — 8-K · Feb 5, 2024
  BioRestorative Therapies, Inc. (BRTX) filed an 8-K on February 5, 2024, to disclose information under Regulation FD and provide financial statements and exhibit
• BRTX Discloses Preliminary Phase 2 Clinical Trial Results via 8-K — 8-K · Feb 1, 2024
  BioRestorative Therapies, Inc. (BRTX) filed an 8-K on February 1, 2024, to disclose a press release regarding preliminary results from its Phase 2 clinical tria

Risk Profile

Risk Assessment: Of BRTX's 34 recent filings, 4 were flagged as high-risk, 20 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Biorestorative Therapies, INC.'s most recent 10-K filing (Mar 26, 2026):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Sandy Lipkins
• Crystal Romano
• Lance Alstodt
• Fred Skolnik, Esq.
• CEO
• Non-CEO Member
• Fred Skolnik
• Dale Broadrick

Industry Context

BioRestorative Therapies operates in the regenerative medicine and biotechnology sectors, focusing on stem cell therapies. The market for regenerative medicine is growing, driven by advancements in cell biology and increasing demand for novel treatments for chronic diseases and injuries. Key competitors include companies developing cell-based therapies, biologics, and advanced medical devices for similar indications.

Top Tags

Biotechnology (5) · financial-results (5) · financials (5) · healthcare (4) · 10-K (4) · amendment (4) · 8-k (3) · corporate-governance (3) · 10-Q (3) · 8-K (3)

Key Numbers

• Aggregate market value of common stock held by non-affiliates: $11,199,773 — as of June 30, 2025, indicating market capitalization
• Shares of common stock outstanding: 25,478,170 — as of March 23, 2026
• Gross proceeds from October 2025 registered direct public offering: $1,085,000 — capital raised to fund operations
• Shares issued in October 2025 offering: 678,125 — contributing to dilution
• Gross proceeds from February 2026 public offering: $5,000,000 — additional capital raised
• Shares issued in February 2026 public offering: 12,560,715 — significant dilution for existing shareholders
• Patients enrolled in Phase 2 clinical trial of BRTX-100: 99 — enrollment completed in February 2026
• Subjects showing >50% improvement in function by 52 weeks: 74% — positive preliminary Phase 2 data for BRTX-100
• Subjects reporting >50% reduction in pain by 52 weeks: 72% — positive preliminary Phase 2 data for BRTX-100
• Stock repurchase program authorized: $2,000,000 — no shares repurchased to date as of June 2025
• Shares offered by selling securityholders: 508,592 — Represents potential dilution without new capital for the company.
• Closing stock price: $1.24 — BRTX's closing price on NASDAQ Capital Market on November 17, 2025.
• Common Stock Outstanding: 8,876,242 — Total shares of common stock currently issued by the company.
• Par value per share: $0.0001 — Nominal value of each common stock share.
• Net Loss: $11.0M — Increased 50.7% from $7.3M in 2024 for the nine months ended September 30, 2025.

Forward-Looking Statements

• {"claim":"The stock price of BRTX may experience short-term volatility due to the dilution effect of the new share issuance.","entity":"BRTX","targetDate":"Q1 2024","confidence":"medium"}
• {"claim":"The company's cash reserves will increase by $1,000,000, improving its liquidity position.","entity":"BioRestorative Therapies, Inc.","targetDate":"Immediately","confidence":"high"}

Frequently Asked Questions